CrystalsFirst utilizes proprietary structural biology technology and generative AI to enhance crystallographic fragment screening and co-structure determination for challenging protein targets. This approach unlocks previously inaccessible chemical matter, facilitating the development of novel therapeutics for pharmaceutical and biotech companies.
Funding
$740K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional crystallographic fragment screening and co-structure determination methods often struggle with challenging protein targets, limiting the exploration of diverse chemical matter and hindering the development of novel therapeutics. Many potential drug targets remain inaccessible due to difficulties in obtaining high-quality structural data.
Solution
CrystalsFirst offers a service platform that leverages structural biology and generative AI to enhance crystallographic fragment screening and co-structure determination, particularly for difficult protein targets. Their approach unlocks previously inaccessible chemical matter, enabling the identification of novel binding pockets and interaction mechanisms. By prioritizing structural data, CrystalsFirst facilitates the design and development of innovative therapeutics for pharmaceutical and biotech companies, accelerating the drug discovery process. The platform's capabilities improve crystallographic quality and unlock the potential for novel inhibition mechanisms.
Target Audience
The primary customers are pharmaceutical and biotech companies seeking to develop novel therapeutics by unlocking challenging protein targets through advanced structural biology and AI-driven drug discovery.
Features
- Proprietary structural biology technology for improved crystal quality and data resolution
- Generative AI algorithms to predict and optimize fragment binding
- Enhanced fragment screening capabilities for challenging protein targets
- Co-structure determination services to visualize fragment-protein interactions
- Identification of novel binding pockets and allosteric sites
- Customized solutions tailored to specific project requirements